Compare Griptha Putra Persada Tbk. (GRPH) vs Indofarma Tbk. (INAF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Griptha Putra Persada Tbk. vs Indofarma Tbk. — how do they compare? Griptha Putra Persada Tbk. trades at Rp137 (market cap 132B, 126.63M 24h volume), while Indofarma Tbk. trades at Rp126 (market cap 390.51B). The key difference: Indofarma Tbk. is far larger — about 3× Griptha Putra Persada Tbk.'s market cap. Which is the better fit depends on your goals.
| GRPH | INAF | |
|---|---|---|
Market Cap | 132B | 390.51B |
Volume | 126.63M | — |
Lot | 1.27M | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Griptha Putra Persada Tbk.
PT Griptha Putra Persada Tbk (the Company), was established based on Notarial Deed No. 26 dated April 14, 2010 of Drs. Ika Slamet Riyono, S.H., notary in Kudus. The Company started its commercial operation in July 1, 2015. The Company’s immediate parent company is PT Mulia Jaya Palma and the ultimate controlling shareholder of the Company is Samuel Jeffrey Christiawan Soegeng.
Read more on GRPH →About Indofarma Tbk.
PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.
Read more on INAF →
